LRRC3B

Across TCGA pan-cancer cohorts, LRRC3B RNA differs between tumor and matched normal tissue in 13 of 18 cancer types tested, making tumor–normal expression one of LRRC3B’s most consistent transcriptional readouts.

The strongest signal is observed in stomach adenocarcinoma (STAD), where LRRC3B RNA is repressed in tumor relative to normal tissue. In most cancer types LRRC3B is over-expressed in tumor, although a few such as STAD and COAD show the opposite, repressed pattern.

STAD, COAD, and BLCA are the cancer types where LRRC3B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LRRC3B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
STAD	Female	All	−0.508	<.001	9	view →
COAD	Male	II,III,IV	−0.280	<.001	9	view →
BLCA	Male	All	−2.220	<.001	8	view →
LUAD	Female	All	−0.160	<.001	8	view →
HNSC	All	All	−0.149	<.001	8	view →
BRCA	Female	II,III,IV	−1.250	<.001	6	view →
READ	All	All	−0.372	.001	5	view →
LUSC	Female	All	−0.198	.001	3	view →
LIHC	All	All	+0.157	<.001	3	view →
PRAD	All	All	−0.218	<.001	2	view →
KIRP	Female	II,III,IV	−0.190	.044	2	view →
KIRC	All	All	+0.159	.007	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 13 lineages.

LRRC3B–STAD

Open the STAD breakdown →